Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Common Equity (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Common Equity for 2 consecutive years, with -$15.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 31.53% to -$15.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.9 million through Dec 2025, up 31.53% year-over-year, with the annual reading at -$15.9 million for FY2025, 31.53% up from the prior year.
  • Common Equity for Q4 2025 was -$15.9 million at NRX Pharmaceuticals, up from -$25.8 million in the prior quarter.
  • The five-year high for Common Equity was -$15.1 million in Q1 2024, with the low at -$35.6 million in Q2 2025.